Affinity Asset Advisors
IRD icon

Affinity Asset Advisors’s Opus Genetics IRD Stock Holding History

Affinity Asset Advisors’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.36M Buy
+900,000
New +$3.74M 0.18% 80

Other funds holding IRD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
BIOS Capital Management
BIOS Capital Management Fort Worth, Texas $34.2M AUM 13.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
AIC
AWM Investment Company New York $1.04B AUM 103.31% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Affinity Asset Advisors's IRD Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Opus Genetics (IRD) in Q3 2026: 900,000 shares worth $4.36M. The stake represents 0.18% of the portfolio and ranks #80 among its holdings.

74 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

  • Affinity Asset Advisors held 900,000 shares of Opus Genetics worth $4.36M as of Q3 2026.
  • Opus Genetics was a new Affinity Asset Advisors position in Q3 2026.
  • Opus Genetics made up 0.18% of Affinity Asset Advisors's portfolio in Q3 2026, its #80 holding.
  • 74 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.